Patent US4366619A successfully refreshed from Google Patents.
Patent US5006290A successfully refreshed from Google Patents.
EP0331391A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for reducing sensitization or irritation in transdermal drug delivery and means therefor
Assignee: Alza Corp
•
Filing: 1989-02-27
•
Granted: —
•
Expires: 2009-02-27
Abstract
Abstract A method and means for reducing sensitization or irritation caused by transdermally delivered drugs, wherein one or more metabolic modulators is coadministered with a sensitizing or irritating drug.
Inventors
- 👤 Michel J. N. Cormier
- 👤 Philip William Ledger
- 👤 Alfred Amkraut
- 👤 Jean Paul Marty
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 19:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K45/00; A61K45/06; A61K31/00; A61K31/045; A61K31/13; A61K31/135; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; A61K38/00; A61K38/005; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K9/0012; A61K9/0014; A61P; A61P3/00; A61P43/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
57 words
A composition of matter for the prevention of undesirable side effects in the skin or mucosa, generated by a drug administered transdermally, comprising: a drug susceptible to being metabolized in the skin or mucosa; and a metabolic modulator capable of modifying the metabolism of said drug; wherein said drug and metabolic modulator are dispersed within a carrier.
Claim 2
Dependent Claim
57 words
A composition of matter for the prevention of undesirable side effects in the skin or mucosa, generated by a drug administered transdermally, comprising: a drug susceptible to being metabolized in the skin or mucosa; and a metabolic modulator capable of modifying the metabolism of said drug; wherein said drug and metabolic modulator are dispersed within a carrier.
Claim 3
Dependent Claim
49 words
A composition as claimed in claim 1, wherein said modulator is present in an amount sufficient to provide administration at a metabolic modifying rate for a predetermined time, and said drug is present in an amount sufficient to provide administration at a therapeutically effective rate for a predetermined time.
Claim 4
Dependent Claim
21 words
A composition as claimed in claim 1 or claim 2 wherein said modulator comprises about 0.1-20 weight percent of said composition.
Claim 5
Dependent Claim
17 words
A composition as claimed in any preceding claim wherein said drug is metabolized by monoamine oxidase activity.
Claim 6
Dependent Claim
16 words
A composition as claimed in claim 6 wherein said metabolic modulator is a monoamine oxoidase inhibitor.
Claim 7
Dependent Claim
28 words
A composition as claimed in any preceding wherein said metabolic modulator has the structure of (C₆H₅)-ROH where R is selected from (CH₂) n CH₂ where n=0-4, and CH=CHCH₂.
Claim 8
Dependent Claim
18 words
A composition as claimed in any preceding claim wherein said drug is propranolol and said modulator is 2-phenyl-1-ethanol.
Claim 9
Dependent Claim
23 words
A composition as claimed in any of claims 1 to 6 wherein said drug is tetracaine and said modulator is 2-phenyl-1-ethanol and/or 3-phenyl-1-propanol.
References Cited (Backward Citations)
BE848880A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.